Segment and Other Information - Summary of Total Revenues (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Product sales, net									$ 1,601,399	$ 1,477,261	$ 1,316,819
Royalties and contract revenues									17,294	10,712	7,984
Total revenues	$ 436,399	$ 411,855	$ 394,386	$ 376,053	$ 396,621	$ 374,181	$ 381,161	$ 336,010	1,618,693	1,487,973	1,324,803
Xyrem
Segment Reporting Information [Line Items]
Product sales, net									1,186,699	1,107,616	955,187
Erwinaze/Erwinase
Segment Reporting Information [Line Items]
Product sales, net									197,340	200,678	203,261
Defitelio/defibrotide
Segment Reporting Information [Line Items]
Product sales, net									133,650	108,952	70,731
Vyxeos
Segment Reporting Information [Line Items]
Product sales, net									33,790	0	0
Prialt® (ziconotide) intrathecal infusion
Segment Reporting Information [Line Items]
Product sales, net									27,361	29,120	26,440
Other
Segment Reporting Information [Line Items]
Product sales, net									$ 22,559	$ 30,895	$ 61,200